These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33072987)

  • 1. A Cost-Effectiveness Analysis of Newborn Screening for Severe Combined Immunodeficiency in the UK.
    Bessey A; Chilcott J; Leaviss J; de la Cruz C; Wong R
    Int J Neonatal Screen; 2019 Sep; 5(3):28. PubMed ID: 33072987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cost-Effectiveness of Expanding the UK Newborn Bloodspot Screening Programme to Include Five Additional Inborn Errors of Metabolism.
    Bessey A; Chilcott J; Pandor A; Paisley S
    Int J Neonatal Screen; 2020 Nov; 6(4):. PubMed ID: 33233828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of newborn screening for severe combined immunodeficiency.
    Van der Ploeg CPB; Blom M; Bredius RGM; van der Burg M; Schielen PCJI; Verkerk PH; Van den Akker-van Marle ME
    Eur J Pediatr; 2019 May; 178(5):721-729. PubMed ID: 30805731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID).
    Chan K; Davis J; Pai SY; Bonilla FA; Puck JM; Apkon M
    Mol Genet Metab; 2011 Nov; 104(3):383-9. PubMed ID: 21810544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Evaluation of Newborn Screening for Severe Combined Immunodeficiency.
    Shih STF; Keller E; Wiley V; Wong M; Farrar MA; Chambers GM
    Int J Neonatal Screen; 2022 Jul; 8(3):. PubMed ID: 35892474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic impact of screening for X-linked Adrenoleukodystrophy within a newborn blood spot screening programme.
    Bessey A; Chilcott JB; Leaviss J; Sutton A
    Orphanet J Rare Dis; 2018 Oct; 13(1):179. PubMed ID: 30309370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness/Cost-Benefit Analysis of Newborn Screening for Severe Combined Immune Deficiency in Washington State.
    Ding Y; Thompson JD; Kobrynski L; Ojodu J; Zarbalian G; Grosse SD
    J Pediatr; 2016 May; 172():127-35. PubMed ID: 26876279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The case for severe combined immunodeficiency (SCID) and T cell lymphopenia newborn screening: saving lives…one at a time.
    Quinn J; Orange JS; Modell V; Modell F
    Immunol Res; 2020 Feb; 68(1):48-53. PubMed ID: 32128663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential costs and benefits of newborn screening for severe combined immunodeficiency.
    McGhee SA; Stiehm ER; McCabe ER
    J Pediatr; 2005 Nov; 147(5):603-8. PubMed ID: 16291349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic neonatal screening for severe combined immunodeficiency and severe T-cell lymphopenia: Analysis of cost-effectiveness based on French real field data.
    Clément MC; Mahlaoui N; Mignot C; Le Bihan C; Rabetrano H; Hoang L; Neven B; Moshous D; Cavazzana M; Blanche S; Fischer A; Audrain M; Durand-Zaleski I
    J Allergy Clin Immunol; 2015 Jun; 135(6):1589-93. PubMed ID: 25840725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of insulin pumps compared with multiple daily injections both provided with structured education for adults with type 1 diabetes: a health economic analysis of the Relative Effectiveness of Pumps over Structured Education (REPOSE) randomised controlled trial.
    Pollard DJ; Brennan A; Dixon S; Waugh N; Elliott J; Heller S; Lee E; Campbell M; Basarir H; White D;
    BMJ Open; 2018 Apr; 8(4):e016766. PubMed ID: 29627802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.
    Sharma P; Boyers D; Boachie C; Stewart F; Miedzybrodzka Z; Simpson W; Kilonzo M; McNamee P; Mowatt G
    Health Technol Assess; 2012; 16(17):1-266. PubMed ID: 22469073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK.
    Batty AJ; Hansen RN; Bloudek LM; Varon SF; Hayward EJ; Pennington BW; Lipton RB; Sullivan SD
    J Med Econ; 2013 Jul; 16(7):877-87. PubMed ID: 23647483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and economic aspects of newborn screening for severe combined immunodeficiency: DEPISTREC study results.
    Thomas C; Durand-Zaleski I; Frenkiel J; Mirallié S; Léger A; Cheillan D; Picard C; Mahlaoui N; Riche VP; Roussey M; Sébille V; Rabetrano H; Dert C; Fischer A; Audrain M
    Clin Immunol; 2019 May; 202():33-39. PubMed ID: 30946917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study Design for an Evaluation of Newborn Screening for SCID in the UK.
    Elliman D
    Int J Neonatal Screen; 2022 Jan; 8(1):. PubMed ID: 35076461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling the Cost-Effectiveness and Budget Impact of a Newborn Screening Program for Spinal Muscular Atrophy and Severe Combined Immunodeficiency.
    Shih STF; Keller E; Wiley V; Farrar MA; Wong M; Chambers GM
    Int J Neonatal Screen; 2022 Jul; 8(3):. PubMed ID: 35892475
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.